| Name | Title | Contact Details |
|---|
Aurinia is a global clinical stage biopharmaceutical company focused on developing and commercializing innovative products to treat identifiable patient populations that are suffering from serious diseases with a high unmet medical need. The company is headquartered in Victoria, BC and focuses its development efforts globally.
Vyripharm® is a disruptive biopharmaceutical innovator in personalized medicine. We are challenging the status quo by shifting medical paradigms through the integration of traditional and alternative medicines. Our purpose is to push the boundaries to drive innovation by turning groundbreaking science into cutting edge diagnostics and therapeutics.
Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis.
Decoding the dark matter of the human genome to uncover novel ways to treat disease Discover More
Ohana is pioneering a new frontier in reproductive medicine. Built upon a world-leading understanding of sperm biology, Ohana has created a best-in-class proprietary platform with broad applications across reproductive medicine.